Jeffrey A. Bluestone, PhD, is Executive Vice Chancellor and Provost, and Director of the Hormone Research Institute at the University of California San Francisco (UCSF). As the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology, Dr. Bluestone is one of the leading immunologists in the field of T-cell activation, co-stimulation, and immune tolerance research that has led to the development of multiple pro-tolerogenic immunotherapies including: CTLA4Ig (the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation), a novel anti-human CD3 antibody being developed to treat Type 1 Diabetes (T1D), and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma. His recent research has focused on the critical role of regulatory T cells (Tregs) in autoimmunity. He has shown that Tregs are key in the control of immune homeostasis but unstable in autoimmune diseases such as T1D. He has spearheaded the use of Tregs as a cell-based therapy to treat T1D. Finally, Dr. Bluestone is an academic leader on a national and international scale. He was the founder and first Director of the Immune Tolerance Network (ITN), the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. Dr. Bluestone has authored more than 400 peer-reviewed publications and has received numerous awards for his work including election to the American Academy of Arts and Sciences and the Institute of Medicine, a Guggenheim Fellowship, and a Distinguished Alumni Award from Cornell University Graduate School of Medical Science.